Which uses of GLP‑1s does insurance cover: weight, diabetes, heart, sleep apnea, PCOS?

Why does the reason on the prescription decide what a plan pays?

US coverage rules follow the approved use, not the medicine itself, so a plan can pay for one use of a drug and refuse another.^1,5

A medicine is what works in your body; a brand is the name on the box. Acetaminophen is a medicine, and Tylenol is one brand of it. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight and heart risk.^7,5

Each brand has a label: the official prescribing document the FDA approves. The label lists the approved uses, called indications. Using a drug for anything else is “off-label”, which the FDA says a prescriber may do when they judge it medically appropriate.¹¹

Plans learn the use from the diagnosis on the prescription and on the prior authorization form (the approval request your prescriber sends). Medicare’s GLP‑1 Bridge, for example, asks prescribers to confirm the drug is for weight “and not for any other approved indication”.¹²

Approved uses on each US label, checked Oct 14, 2026

None of these seven labels lists PCOS or prediabetes as an approved use.^5,6,7,8,9,10 Sources: current US labels.

How do Medicare and Medicaid treat each use?

Medicare drug plans can’t pay for weight loss but can pay for other approved uses, and Medicaid must cover the diabetes, heart and sleep apnea uses.^1,2

The rule comes from one line of federal law. It lets Medicaid leave out drugs “when used for anorexia, weight loss, or weight gain”.³ Medicare Part D carries the same exclusion.⁴

Everything else turns on a “medically accepted indication”. The law defines it as a use the FDA approved, or one supported by one of three drug reference books, called compendia.³ Part D covers drugs only for these uses.⁴

• Medicare Part D plans can cover GLP‑1s for “type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea”, KFF says.¹ People with type 2 diabetes, moderate-to-severe sleep apnea or MASH must go through their Part D plan.¹²
• Medicare for weight runs only through the temporary GLP‑1 Bridge, from July 1, 2026, to December 31, 2027, at $50 a month.¹
• Medicaid must cover diabetes, Wegovy’s heart use since March 2024 and Zepbound’s sleep apnea use since December 2024. Weight is a state choice. KFF counted 13 states in January 2026; our October 14, 2026, check found 10.^2,28

KFF’s Medicaid analysis doesn’t mention the MASH use, so we don’t say either way.² The full Medicare picture is in how Medicare covers GLP‑1 medicines. State rules are in Medicaid by state. Every dated change for 2026 and 2027 is in what’s changing in GLP‑1 coverage.

Massachusetts shows the split in practice. From July 3, 2026, MassHealth, its Medicaid program, stopped covering GLP‑1s used only for weight in adults.²⁹ WBUR reported that at least 22,000 people were affected.¹⁴ The heart, sleep apnea and MASH uses stayed covered, with their own criteria.^29,13

The heart and liver uses have their own page: Wegovy for heart and fatty liver. So does Zepbound for sleep apnea.

What do employer and private plans do?

Employer plans choose which uses to cover, and many cover diabetes but not weight; a plan’s exclusion wording can matter as much as the label.^19,20

Covering GLP‑1s for weight is optional for employers. KFF’s 2025 survey looked at firms that offer health benefits. Of those with 200 to 999 workers, 16% covered GLP‑1s mainly for weight. Of those with 5,000 or more workers, 43% did.²⁰ A law firm advising employers wrote that many “want to limit their coverage of GLP‑1s to only diabetes”.¹⁹

Insurers publish the criteria they use, and these show how the use gets checked. We quote dated documents from two insurers as examples. We don’t rank or recommend any insurer.

• Diabetes brands. Cigna’s policy for Ozempic, Mounjaro and similar drugs approves them for type 2 diabetes. It lists weight loss, type 1 diabetes and prediabetes among uses it won’t cover (reviewed June 3, 2026).¹⁵
• Fatty liver (MASH). A May 2026 Cigna policy for some individual plans can approve Wegovy for MASH even where weight-loss drugs aren’t a benefit. It asks for proof of F2 or F3 scarring and a specialist prescriber.¹⁶
• Sleep apnea. The Blue Cross Blue Shield federal employee policy for Zepbound, effective July 1, 2026, sets criteria for weight only. It calls Zepbound “investigational for all other indications”.¹⁸

One federal court has sided with a plan on exclusion wording. In June 2026, in what a law firm called a case of first impression, a federal court in Washington, DC, upheld a plan’s refusal to pay for Zepbound prescribed for sleep apnea. The plan excluded weight-loss medications, and the court said that exclusion applied.¹⁹ Federal workers’ plans are covered in TRICARE, the VA and federal plans.

Is a GLP‑1 covered for PCOS or prediabetes?

No current US GLP‑1 label lists polycystic ovary syndrome (PCOS), so a request for PCOS alone is a request for an off-label use.^5,6,7,8,9,10

PCOS is a set of symptoms caused by a hormone imbalance. It can affect periods, fertility, body hair and metabolism.²⁷

Medicare Part D can pay for an off-label use only if one of the three reference books supports it.^3,4 Those books are paid subscriptions, and we could not check what they say about GLP‑1s and PCOS.

Private plans differ. Cigna’s September 2026 criteria for Foundayo, a weight pill, list PCOS among weight-related conditions. With one of those conditions, the BMI needed drops from 30 to 27.¹⁷ In that case the plan is paying for weight management, and PCOS is the reason a BMI of 27 counts.

Prediabetes (blood sugar above normal but below the diabetes range) works the same way. Cigna’s diabetes policy won’t cover diabetes brands for prediabetes.¹⁵ Medicare’s Bridge counts prediabetes toward its weight rules at a BMI of 27 or more.¹²

A worked example, by our arithmetic, for someone 5 ft 5 in (165 cm) tall. A BMI of 27 is about 162 lb (73 kg). A BMI of 30 is about 180 lb (82 kg).

Are teenagers covered?

Two weight brands are FDA-approved from age 12, and Medicaid must cover GLP‑1s for children when medically necessary; private plans set their own age rules.^5,9,2

• Wegovy injection: teens 12 and older with obesity. Its teen trial enrolled teens at or above the 95th BMI percentile.⁵ That means a higher BMI than 95 in 100 children of the same age and sex.
• Wegovy tablets and the 7.2 mg dose: safety not established in children.⁵
• Saxenda: 12 and older weighing over 132 lb (60 kg) with obesity.⁹ Novo Nordisk says its last shipments to wholesalers are in late January 2027.²⁵
• Mounjaro: type 2 diabetes from age 10.⁸ Zepbound, Ozempic and Foundayo are not established in children.^6,7,10

A 2023 American Academy of Pediatrics guideline says doctors should offer weight-loss medicine to teens 12 and older with obesity. It is added to lifestyle treatment, not used instead.²¹

How a trial works, in brief:

• People are split at random into groups. One group gets a dummy injection (placebo) with no medicine in it.
• Both groups get the same diet and activity advice.
• The gap between the groups is what the medicine added. An average is not a promise for any one teen.

Put the other way, about 27 in 100 teens on Wegovy did not lose 5%.²² Stomach effects were common: 42 in 100 felt sick, against 18 in 100 on the dummy injection.⁵ Gallstones affected 4 in 100 teens on Wegovy and none on the dummy.²²

Medicaid. Its children’s benefit, EPSDT (Early and Periodic Screening, Diagnostic and Treatment), covers under-21s. States must provide medically necessary treatment even if their Medicaid plan doesn’t list it.²³ KFF says this makes GLP‑1 coverage required for children when deemed medically necessary.² When MassHealth ended adult weight coverage, it kept an EPSDT route for under-21s.²⁹

CHIP (the Children’s Health Insurance Program) depends on how your state runs it. CHIP run through Medicaid must give EPSDT. A separate CHIP program can instead copy a benchmark plan, such as a state employee plan.²⁴

Private plans set their own age limits. The federal employee Blue Cross policy for Zepbound requires age 18 or older, as does Cigna’s Foundayo policy, matching both labels.^18,17

What should you ask your plan?

Ask which use your prescription is for, whether your plan covers that use, and what its prior authorization asks for, in writing.

1. 1The use. Weight, diabetes, heart risk, sleep apnea or MASH? Ask your prescriber which diagnosis goes on the request.
2. 2The drug list. Ask for your plan’s formulary (its list of covered drugs). Check the marks next to your drug: what PA, ST and QL mean.
3. 3The exclusions. Ask whether the plan excludes weight-loss drugs, and whether it applies that exclusion to your use.¹⁹
4. 4The criteria document. Insurers publish the criteria for each drug; ask for the version your plan uses.^15,16,18
5. 5If the answer is no. Ask for the reason in writing. The routes are in how GLP‑1 appeals work and prior authorization, step by step.

Questions people ask

How we researched this

More on insurance

USUnited StatesHow does Medicare cover GLP‑1 medicines like Ozempic, Wegovy and Zepbound?USUnited StatesWill your employer or Marketplace plan cover Wegovy or Zepbound in 2027?USUnited StatesWas your Wegovy or Zepbound denied? How do insurance appeals work?